Pediatric Rhabdomyosarcoma Workup: Laboratory Studies, Imaging Studies, Procedures

Laboratory Studies

The following studies are indicated in rhabdomyosarcoma:

• CBC count: Anemia may be present because of inflammation, or pancytopenia may be present from bone marrow involvement.
• Liver function tests, including measurement of lactic acid dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, and bilirubin levels: Metastatic disease of the liver may affect values of these proteins. Liver function must be assessed before chemotherapy.
• Renal function tests, including measurements of BUN and creatinine levels: Renal function must be assessed before chemotherapy.
• Urinalysis (UA): Hematuria may indicate involvement of the genitourinary (GU) tract.
• Blood electrolyte and chemistry, including evaluation of sodium, potassium, chlorine, carbon dioxide, calcium, phosphorous, and albumin values: Assess for abnormalities before chemotherapy.

Imaging Studies

See the list below:

• Plain radiography: Radiography of the primary site and of the chest is helpful in determining the presence of calcifications and bone involvement of the primary tumor and to search for metastatic lung lesions.
• CT scanning
  • Obtain a chest CT scan to evaluate for metastases to the lungs. Chest CT scanning is best performed before surgery to avoid atelectasis, which can be confused with metastasis.
  • A CT scan of the primary site may also be helpful in evaluating for bone erosion, if present, and to follow up the patient's response to therapy.
  • Obtain a CT scan of the liver in patients with abdominal or pelvic primary tumors to assess for metastatic spread. Ultrasonography is an alternative.
• MRI: MRI improves definition of the mass and its invasion of adjacent organs, especially in orbital, paraspinal, or parameningeal regions. Obtain an MRI of the head if the patient is symptomatic at diagnosis.
• Bone scanning: Search for metastases to the bones.
• Ultrasonography: Obtain sonograms of the liver in patients with abdominal or pelvic tumors. CT scanning is an alternative.
• Echocardiography: Assess cardiac function before chemotherapy.

Procedures

See the list below:

• Biopsy: Open biopsy best enables adequate tissue sampling for diagnosis and molecular studies. Core needle biopsy is an alternative. Depending on the location, definitive surgery can be postponed to allow for neoadjuvant chemotherapy to shrink the tumor.
• Cytogenetics, fluorescent in situ hybridization (FISH)
  • This study helps in determining if the translocations t(1;13) or t(2;13), which are associated with the alveolar subtype, are present.
  • FISH also helps in the diagnosis to assess for break-apart of the FKHR gene, though this test will miss the rare variants that don’t involve FKHR.
  • FISH is most sensitive for these translocations and can be helpful in evaluating residual disease.
• Reverse transcriptase–polymerase chain reaction (RT-PCR) testing
  • When cytogenetic testing is unavailable (eg, culture failure) or when its results are uninformative, order a RT-PCR reaction to assess for the characteristic translocations associated with alveolar rhabdomyosarcoma (ARMS) and other small, round blue-cell tumors of childhood.
  • In many centers, the use of RT-PCR to screen for a panel of translocations associated with soft tissue sarcomas is becoming a routine adjunct to morphologic analysis to help ascertain the diagnosis.
• Bone marrow aspiration and biopsy: Assess for metastatic spread to bone marrow.

Histologic Findings

Rhabdomyosarcoma is one of the small, round blue-cell tumors of childhood. Occasionally, these types of tumors can be difficult to differentiate. Rhabdomyosarcoma cells tend to have variable differentiation along the myogenesis pathway and may appear as strap cells or myotubes that sometimes contain muscle cross-striations. Rhabdomyosarcoma cells may demonstrate positive immunohistochemical results for muscle-specific markers, such as myoglobin, actin, and desmin.

Cells from the rhabdomyosarcoma subtypes have the following distinctive features:

• Botryoid: The cambium layer is characteristic, containing a condensation of loose tumor cells below an epithelial surface.
• Alveolar: Cells line up along membranes that may be imperceptibly thin or that may be obvious collagen bands resembling the lung alveoli. A tumor should be classified as this type if any portion of it appears to be alveolar.
• Undifferentiated: No evidence of myogenesis differentiation is usually present.

Treatment & Management

Timothy P Cripe, MD, PhD, FAAP Chief, Division of Hematology/Oncology/BMT, Gordon Teter Endowed Chair in Pediatric Cancer, Nationwide Children's Hospital; Professor of Pediatrics, Ohio State University College of Medicine

Timothy P Cripe, MD, PhD, FAAP is a member of the following medical societies: American Academy of Pediatrics, American Association for the Advancement of Science, American Association for Cancer Research, American Pediatric Society, American Society of Gene and Cell Therapy, American Society of Pediatric Hematology/Oncology, Connective Tissue Oncology Society, Society for Pediatric Research, Children's Oncology Group

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Steven K Bergstrom, MD Department of Pediatrics, Division of Hematology-Oncology, Kaiser Permanente Medical Center of Oakland

Steven K Bergstrom, MD is a member of the following medical societies: Alpha Omega Alpha, Children's Oncology Group, American Society of Clinical Oncology, International Society for Experimental Hematology, American Society of Hematology, American Society of Pediatric Hematology/Oncology

Chief Editor

Max J Coppes, MD, PhD, MBA Executive Vice President, Chief Medical and Academic Officer, Renown Heath

Max J Coppes, MD, PhD, MBA is a member of the following medical societies: American College of Healthcare Executives, American Society of Pediatric Hematology/Oncology, Society for Pediatric Research

Acknowledgements

Samuel Gross, MD Professor Emeritus, Department of Pediatrics, University of Florida College of Medicine; Clinical Professor, Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine; Adjunct Professor, Department of Pediatrics, Duke University School of Medicine

Samuel Gross, MD is a member of the following medical societies: American Association for Cancer Research, American Society for Blood and Marrow Transplantation, American Society of Clinical Oncology, American Society of Hematology, and Society for Pediatric Research

References

1. Punyko JA, Mertens AC, Baker KS, et al. Long-term survival probabilities for childhood rhabdomyosarcoma. A population-based evaluation. Cancer. 2005 Apr 1. 103(7):1475-83. [Medline].
2. Nelson R. New Drug Combos Promising in Higher-Risk Rhabdomyosarcoma. Medscape Medical News. Available at http://www.medscape.com/viewarticle/826251. Accessed: June 9, 2014.
3. Mascarenhas L, Meyer WH, Lyden E. et al. Randomized phase II trial of bevacizumab and temsirolimus in combination with vinorelbine (V) and cyclophosphamide (C) for first relapse/disease progression of rhabdomyosarcoma (RMS): A report from the Children’s Oncology Group (COG). ASCO Meeting Abstracts. Available at http://abstracts.asco.org/144/AbstView_144_126151.html. Accessed: June 9, 2014.
4. Hawkins DS, Anderson JR, Mascarenhas L, et al. Vincristine, dactinomycin, cyclophosphamide (VAC) versus VAC/V plus irinotecan (VI) for intermediate-risk rhabdomyosarcoma (IRRMS): A report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. ASCO Meeting Abstracts. Available at http://abstracts.asco.org/144/AbstView_144_126983.html. Accessed: June 9, 2014.
5. Rao AA, Naheedy JH, Chen JY, Robbins SL, Ramkumar HL. A clinical update and radiologic review of pediatric orbital and ocular tumors. J Oncol. 2013. 2013:975908. [Medline]. [Full Text].
6. Rahman HA, Sedky M, Mohsen I, Taha H, Loaye I, Zaghloul MS, et al. Outcome of pediatric parameningeal rhabdomyosarcoma. The Children Cancer Hospital, Egypt, experience. J Egypt Natl Canc Inst. 2013 Jun. 25(2):79-86. [Medline].
7. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 1999 Jul 29. 341(5):342-52. [Medline].
8. Stout AP. Rhabdomyosarcoma of the skeletal muscles. Ann Surg. 1946. 123:447-72.
9. Pappo AS, Shapiro DN, Crist WM, Maurer HM. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol. 1995 Aug. 13(8):2123-39. [Medline].
10. Barr FG. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol. 1997 Nov-Dec. 19(6):483-91. [Medline].
11. Sumegi J, Streblow R, Frayer RW, et al. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. Genes Chromosomes Cancer. 2010 Mar. 49(3):224-36. [Medline]. [Full Text].
12. Merlino G, Helman LJ. Rhabdomyosarcoma--working out the pathways. Oncogene. 1999 Sep 20. 18(38):5340-8. [Medline].
13. Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol. 2008 May 10. 26(14):2384-9. [Medline].
14. Bisogno G, Ferrari A, Prete A, et al. Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma. Eur J Cancer. 2009 Nov. 45(17):3035-41. [Medline].
15. Mazzoleni S, Bisogno G, Garaventa A, et al. Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma. Cancer. 2005 Jul 1. 104(1):183-90. [Medline].
16. Arndt CA. Risk stratification of rhabdomyosarcoma. Am Soc Clin Oncol Educ Book. 2013. 2013:415-9. [Medline].
17. Gripp KW. Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet. 2005 Aug 15. 137C(1):72-7. [Medline].
18. Grufferman S, Ruymann F, Ognjanovic S, Erhardt EB, Maurer HM. Prenatal X-ray exposure and rhabdomyosarcoma in children: a report from the children''s oncology group. Cancer Epidemiol Biomarkers Prev. 2009 Apr. 18(4):1271-6. [Medline]. [Full Text].
19. Qualman SJ, Coffin CM, Newton WA, et al. Intergroup Rhabdomyosarcoma Study: update for pathologists. Pediatr Dev Pathol. 1998 Nov-Dec. 1(6):550-61. [Medline].
20. De Corti F, Dall'Igna P, Bisogno G, et al. Sentinel node biopsy in pediatric soft tissue sarcomas of extremities. Pediatr Blood Cancer. 2009 Jan. 52(1):51-4. [Medline].
21. Wolden SL, Wexler LH, Kraus DH, et al. Intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 2005 Apr 1. 61(5):1432-8. [Medline].
22. Yock T, Schneider R, Friedmann A, et al. Proton radiotherapy for orbital rhabdomyosarcoma: clinical outcome and a dosimetric comparison with photons. Int J Radiat Oncol Biol Phys. 2005 Nov 15. 63(4):1161-8. [Medline].
23. Million L, Anderson J, Breneman J, et al. Influence of Noncompliance With Radiation Therapy Protocol Guidelines and Operative Bed Recurrences for Children With Rhabdomyosarcoma and Microscopic Residual Disease: A Report From the Children's Oncology Group. Int J Radiat Oncol Biol Phys. 2011 Jun 1. 80(2):333-8. [Medline].
24. Currier MA, Adams LC, Mahller YY, et al. Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. Cancer Gene Ther. 2005 Apr. 12(4):407-16. [Medline].
25. Modak S, Guo HF, Humm JL, et al. Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9. Cancer Biother Radiopharm. 2005 Oct. 20(5):534-46. [Medline].
26. Bersani F, Taulli R, Accornero P, et al. Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma. Eur J Cancer. 2008 Apr. 44(6):876-84. [Medline].
27. Cao L, Yu Y, Darko I, et al. Addiction to elevated insulin-like growth factor i receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res. 2008 Oct 1. 68(19):8039-48. [Medline].
28. Klingebiel T, Boos J, Beske F, et al. Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial. Pediatr Blood Cancer. 2008 Apr. 50(4):739-45. [Medline].
29. Fulda S. Molecular Targeted Therapies for Rhabdomyosarcoma: Focus on Hedgehog and Apoptosis Signaling. Klin Padiatr. 2013 May. 225(3):115-119. [Medline].
30. Pappo AS, Lyden E, Breitfeld P, et al. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J Clin Oncol. 2007 Feb 1. 25(4):362-9. [Medline].
31. Punyko JA, Mertens AC, Gurney JG, et al. Long-term medical effects of childhood and adolescent rhabdomyosarcoma: a report from the childhood cancer survivor study. Pediatr Blood Cancer. 2005 Jun 15. 44(7):643-53. [Medline].
32. Boggs W. Presenting Characteristics Should Drive Rhabdomyosarcoma Staging in Kids. Medscape. Sep 2 2013. Available at http://www.medscape.com/viewarticle/810327. Accessed: Sep 10 2013.
33. Pappo AS, Shapiro DN, Crist WM. Rhabdomyosarcoma. Biology and treatment. Pediatr Clin North Am. 1997 Aug. 44(4):953-72. [Medline].
34. Weiss AR, Lyden ER, Anderson JR, Hawkins DS, Spunt SL, Walterhouse DO, et al. Histologic and Clinical Characteristics Can Guide Staging Evaluations for Children and Adolescents With Rhabdomyosarcoma: A Report From the Children's Oncology Group Soft Tissue Sarcoma Committee. J Clin Oncol. 2013 Sep 10. 31(26):3226-3232. [Medline].

Axial CT scan of rhabdomyosarcoma in the left middle ear. Image provided by Suresh Muhkerji, MD, Department of Radiology, University of North Carolina Hospitals.